Abivax SA AI Stock Analysis
Want to see FR:ABVX full AI Analyst Report?
Abivax SA (ABVX) AI Stock Analysis
Abivax SA
(Paris:ABVX)
The score is primarily held back by weak financial performance—ongoing large losses, unstable revenue (including a 2025 drop to zero), and persistent negative free cash flow—despite an improved 2025 balance sheet with low leverage. Technicals add further pressure due to a broad downtrend and negative momentum indicators. Valuation provides limited support because earnings are negative and there is no dividend yield.
Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 6.93B
- Dividend Yield
- ―
- Average Volume (3M)
- 130.18K
- Price to Earnings (P/E)
- -16.8
- Beta (1Y)
- 1.19
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- France
- Employees
- 98
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Abivax SA Business Overview & Revenue Model
Company Description
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX...
How the Company Makes Money
Abivax SA does not have a disclosed commercial product revenue stream and, as a clinical-stage biopharmaceutical company, its operations are primarily funded through external financing rather than sales. The company’s cash inflows typically come from...
Abivax SA Financial Statement Overview
Summary
Financial performance is constrained by large and widening net/operating losses and consistently negative operating and free cash flow (high cash burn). The main offset is an improved 2025 balance sheet with low leverage and higher equity, which supports liquidity/runway, but the business remains reliant on external funding given minimal/unstable revenue (including a drop to zero in 2025).
Income Statement
12Very NegativeBalance Sheet
55NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -2.02M | 0 | 10.79M | 4.62M | 4.58M | 37.00K |
| Gross Profit | -3.09M | -1.07M | 10.79M | 4.49M | 4.51M | -119.00K |
| EBITDA | -278.97M | -249.55M | -167.68M | -133.21M | -53.31M | -42.20M |
| Net Income | -352.75M | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | ||||||
| Total Assets | 462.21M | 584.34M | 205.23M | 327.06M | 73.35M | 110.36M |
| Cash, Cash Equivalents and Short-Term Investments | 410.68M | 530.38M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 1.21M | 32.09M | 97.36M | 55.46M | 39.16M | 53.45M |
| Total Liabilities | 95.94M | 129.14M | 164.64M | 131.05M | 71.47M | 81.59M |
| Stockholders Equity | 366.27M | 455.20M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | ||||||
| Free Cash Flow | -147.65M | -162.23M | -154.72M | -97.39M | -69.55M | -47.30M |
| Operating Cash Flow | -147.46M | -162.09M | -154.07M | -97.13M | -65.58M | -45.66M |
| Investing Cash Flow | 4.25M | -13.72M | 15.76M | -8.10M | -3.73M | -1.46M |
| Financing Cash Flow | 564.11M | 553.80M | 28.21M | 335.29M | 32.21M | 82.68M |
Abivax SA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Negative. The current price of 79.10 is below the 20-day moving average (MA) of 79.86, below the 50-day MA of 84.13, and below the 200-day MA of 97.99, indicating a bearish trend. The MACD of -0.93 indicates Negative momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABVX.
Abivax SA Peers Comparison
Overall Rating
FR:VLA51Neutral
FR:IPH48Neutral
FR:ALCLS46Neutral
FR:TNG45Neutral
FR:DBV44Neutral
FR:ABVX44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 51Neutral | EUR 488.58M | -2.85 | -152.15% | ― | -27.19% | -117.39% | |
| 48Neutral | EUR 134.04M | -2.35 | 152.56% | ― | -29.48% | 7.91% | |
| 46Neutral | EUR 76.38M | -1.78 | -94.14% | ― | -5.98% | -8.67% | |
| 45Neutral | EUR 200.64M | -4.31 | -29.36% | ― | 189.81% | 38.50% | |
| 44Neutral | EUR 618.29M | -3.62 | -121.83% | ― | ― | 45.11% | |
| 44Neutral | EUR 6.93B | -16.79 | -85.88% | ― | ― | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ABVX | Abivax SA | 79.10 | -18.10 | -18.62% | |
| FR:IPH | Innate Pharma S.A. | 1.20 | -0.37 | -23.37% | |
| FR:DBV | Dbv Technologies SA (UK) | 1.97 | -0.43 | -17.87% | |
| FR:TNG | Transgene SA | 0.72 | -0.58 | -44.75% | |
| FR:VLA | Valneva (0OB3) | 2.57 | -1.26 | -32.88% | |
| FR:ALCLS | Cellectis SA | 1.06 | -2.64 | -71.42% |
Abivax SA Corporate Events
Abivax to Present at Five Investor Conferences This Fall
Abivax announced plans to participate in five investor and healthcare conferences from November 9 to December 3, 2026, with events scheduled in Boston, London, Frankfurt, Miami and New York. Company representatives will take part in fireside chats an...
Abivax Updates Share Capital and Voting Rights Structure as of September 30, 2026
Abivax disclosed updated capital and voting rights data as of September 30, 2026, reporting a share capital of €875,481 represented by 87,541,485 shares and 88,796,742 theoretical and exercisable voting rights. The publication complies with French co...
Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026
Abivax SA will showcase seven scientific abstracts on its lead drug candidate obefazimod at United European Gastroenterology Week 2026 in Barcelona, highlighting extensive clinical and preclinical data in ulcerative colitis and related inflammatory c...
Abivax Updates Share Capital and Voting Rights Structure as of August 31, 2026
Abivax reported that, as of August 31, 2026, its share capital consists of 87,271,525 shares, corresponding to 88,526,782 theoretical and exercisable voting rights under French market regulations. The disclosure, made in line with requirements of the...
Abivax bolsters leadership and balance sheet as obefazimod nears commercialization
Abivax has overhauled its leadership team as it prepares for potential commercialization of obefazimod, appointing Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer. These changes are designed to bolster medical, CMC, qua...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 25, 2026
